Results 251 to 260 of about 291,218 (316)
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source
Detection of Monocyte Subsets in the Bone Marrow of Patients With Acute Myeloid Leukemia and Its Clinical Significance. [PDF]
Zhang L +7 more
europepmc +1 more source
This study develops an iridium‐based nanozyme (IIN@M) with superior enzyme‐like activity and photothermal performance. It disrupts intracellular redox balance by generating reactive oxygen species and depleting glutathione, which synergistically induces ferroptosis, pyroptosis, and immunogenic cell death.
Lijun Ding +7 more
wiley +1 more source
Expression and prognostic value of FKBP51 in Hodgkin lymphoma. [PDF]
Varricchio S +14 more
europepmc +1 more source
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang +7 more
wiley +1 more source
Bone Marrow CD8+ Cytotoxic T-lymphocyte Subset: A Prognostic Indicator in Acute Myeloid Leukemia. [PDF]
Osman RA +6 more
europepmc +1 more source
Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian +7 more
wiley +1 more source

